Letter by Barakat et al Regarding Article, “Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the meta-analysis by Golwala et al1 that aimed to assess the benefits of an implantable cardioverter-defibrillator (ICD) for the primary prevention of mortality in patients with nonischemic cardiomyopathy. Their primary analysis demonstrated a 23% risk reduction in all-cause mortality in favor of ICD (hazard ratio, 0.77; 95% confidence interval, 0.64–0.91). They performed a subgroup analysis of the 2 trials that, according to the authors, compared ICD plus cardiac resynchronization therapy (CRT-D) plus optimal medical therapy with CRT-pacemaker …